Indications and clinical application scope of bichizumab

Bimekizumab (Bimekizumab) is a humanized IgG1 monoclonal antibody that works by dually inhibiting IL-17A and IL-17F cytokines and is widely used in a variety of chronic inflammatory diseases. The drug was approved by the FDA for the treatment of moderate to severe plaque psoriasis in adults in October 2023, and has been rapidly expanded to multiple indications in joints and skin systems, reflecting the breadth and importance of its therapeutic scope.

In terms of psoriasis, Bicizumab has shown significant efficacy in inhibiting skin inflammation and reducing itching and scaling. It is currently the world's first biological agent to target both IL-17A and IL-17F at the same time. It is suitable for adult patients who are suitable for systemic treatment or phototherapy. For patients with psoriatic arthritis (PsA) accompanied by joint damage, Biqi beads can relieve joint pain and swelling and improve skin symptoms. Its efficacy has been approved by the FDA and European regulatory agencies. Furthermore, for patients with non-radiographic axial spondyloarthropathy (nr‑axSpA) and ankylosing spondylitis (AS), Biqiziz also demonstrated the ability to improve the condition by reducing inflammatory markers such as CRP and imaging.

It is worth noting that Bicizumab has also made breakthroughs in another complex and difficult-to-treat field - Hidradenitis Suppurativa (HS). The US FDA approved it in November 2024 for the treatment of moderate to severe HS, meeting the rare drug needs of this highly painful skin disease. In addition, clinical studies have shown that Bicizumab has rapid and long-lasting efficacy in each of the above diseases, with good safety, making it an important therapeutic force in the field of autoimmune and inflammatory diseases.

In short, bichizumab has been approved for key indications in many countries around the world, covering various IL-17-mediated diseases such as psoriasis, psoriatic arthritis, (non-)axial spondyloarthropathy and hidradenitis suppurativa.IL-17 mediated diseases. Its unique dual-targeting mechanism and sustained efficacy lead a new trend in biological treatment, showing significant advantages in improving quality of life and controlling long-term inflammation.

Reference materials:https://www.drugs.com/bimekizumab.html